Home » Stocks » SNSE

Sensei Biotherapeutics, Inc. (SNSE)

Stock Price: $11.64 USD -0.07 (-0.56%)
Updated Jun 21, 2021 12:59 PM EDT - Market open
Market Cap 357.89M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 18.90M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 21
Last Price $11.64
Previous Close $11.70
Change ($) -0.07
Change (%) -0.56%
Day's Open 11.93
Day's Range 11.53 - 12.19
Day's Volume 37,010
52-Week Range 9.05 - 26.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

According to the Double Buys page, a Premium feature of GuruFocus, five stocks that had multiple guru and insider buys during the second quarter are PennyMac Financial Services inc. ( PFSI , Financial),...

Other stocks mentioned: HAYW, PFSI, PTON, VST
1 week ago - GuruFocus

– Data continue to show that SNS-301 in combination with pembrolizumab is well tolerated –

1 month ago - GlobeNewsWire

- ImmunoPhage™ platform programs and the VISTA program continue to advance -

1 month ago - GlobeNewsWire

BOSTON and ROCKVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a  clinical-stage immunotherapy company focused on the discovery and development of next generati...

1 month ago - GlobeNewsWire

Entrepreneurial leader brings expertise growing biotech platform companies Entrepreneurial leader brings expertise growing biotech platform companies

2 months ago - GlobeNewsWire

-Successfully completed upsized IPO in February 2021 raising approximately $152.6 million in gross proceeds –

2 months ago - GlobeNewsWire

There are many reasons an insider might sell. But there is only one reason for insider buying; insiders think the stock will trade higher.

Other stocks mentioned: DHR, DTE, IRWD, NLS, PRMW, TREE
3 months ago - InvestorPlace

BOSTON and ROCKVILLE, Md., March 09, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutic...

3 months ago - GlobeNewsWire

If the insiders are buying, other investors should at least pay attention. These seven stocks are ones to keep an eye on here.

Other stocks mentioned: CERN, DD, HSIC, INCY, MTD, NUS
3 months ago - InvestorPlace

BOSTON and ROCKVILLE, Md., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics...

4 months ago - GlobeNewsWire

BOSTON and ROCKVILLE, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics...

4 months ago - GlobeNewsWire

BOSTON & ROCKVILLE, Md.--Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced...

4 months ago - Business Wire

Sensei Biotherapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

5 months ago - SEC

Sensei Biotherapeutics, a Phase 2 biotech developing bacteriophage-based therapies for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

5 months ago - NASDAQ

Sensei Biotherapeutics, a clinical-stage cancer immunotherapy company that opened a Boston research and development hub last year, has attracted high-profile investors for its $30 million Series B round.

5 months ago - BostInno

About SNSE

Sensei Biotherapeutics is a clinical-stage immunotherapy company engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. Monoclonal antibodies targeting the programmed cell death protein 1, or PD-1, and its related ligand, or PD-L1, have emerged as one of the most promising classes of therapeutics for the treatment of cancer. However, in a majority of patients they generally fail to produce meaningful results. Drugs utilizing PD-1 blockade have been approved by the FDA to treat at le... [Read more...]

Industry
Biotechnology
IPO Date
Feb 4, 2021
CEO
John Celebi
Employees
30
Stock Exchange
NASDAQ
Ticker Symbol
SNSE
Full Company Profile

Financial Performance

Financial Statements